Xing Sun

Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α

Aimee Y. Yu, Larissa A. Shimoda, Narayan V. Iyer et al. · Journal of Clinical Investigation · 1999 · 655 citations · Full text

Life Sciences, Genetics, Physiology +16

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

Shun Lü, Lin Wu, Hong Jian et al. · The Lancet Oncology · 2022 · 243 citations

Medicine, Oncology, Pharmacology +17

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial

Shun Lü, Lin Wu, Hong Jian et al. · The Lancet Respiratory Medicine · 2023 · 200 citations

Medicine, Oncology, Pharmacology +16

Sequential DICE combined with<scp>l</scp>-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma

Lihua Dong, Lijuan Zhang, Wenjia Wang et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 44 citations

Medicine, Oncology, Radiation Oncology +15

Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer

Yunpeng Yang, Bin Wu, Linian Huang et al. · Translational Lung Cancer Research · 2019 · 36 citations · Full text

Medicine, Oncology, Pharmacology +14